1. Platelet-rich plasma for the treatment of knee osteoarthritis: an expert opinion and proposal for a novel classification and coding system
- Author
-
Gerard A. Malanga, Lisa A. Fortier, Brian J. Cole, Giuseppe Filardo, Norimasa Nakamura, Diego Delgado, Mikel Sánchez, Elizaveta Kon, Steven Sampson, Alberto Giuffrida, Scott A. Rodeo, Berardo Di Matteo, Chris Hyunchul Jo, Andrea Dorotei, Jason L. Dragoo, Allan Mishra, Jeremy Magalon, Istituto Clinico Humanitas [Milan] (IRCCS Milan), Humanitas University [Milan] (Hunimed), Rush University Medical Center [Chicago], University of Colorado [Colorado Springs] (UCCS), Pacific Biosciences [Menlo Park], Pacific Biosciences of California, Cornell University [New York], David Geffen School of Medicine [Los Angeles], University of California [Los Angeles] (UCLA), University of California (UC)-University of California (UC), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), New jersey Center for Biomaterials, Rutgers, The State University of New Jersey [New Brunswick] (RU), Rutgers University System (Rutgers)-Rutgers University System (Rutgers), Osaka University Dental Hospital [Osaka], New York University [New York] (NYU), NYU System (NYU), University of California (UC), Université Francisco de Vitoria = Universidad Francisco de Vitoria (UFV), University of California-University of California, and University of California
- Subjects
0301 basic medicine ,Prp ,Anabolism ,hip ,Clinical Biochemistry ,knee ,Osteoarthritis ,Bioinformatics ,03 medical and health sciences ,0302 clinical medicine ,Drug Discovery ,growth factors ,medicine ,Pharmacology ,business.industry ,medicine.disease ,3. Good health ,Distress ,Coding system ,osteoarthritis ,030104 developmental biology ,injection ,classification ,030220 oncology & carcinogenesis ,Platelet-rich plasma ,Expert opinion ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; Introduction Platelet-rich plasma (PRP) is able to modulate the joint environment by reducing the inflammatory distress and promoting tissue anabolism. Therefore, it has gained increasing popularity among clinicians in the treatment of osteoarthritis (OA), and it is currently proposed beside consolidated options such as viscosupplementation. Areas covered A systematic review of all available meta-analyses evaluating intra-articular PRP injections in patients affected by knee OA was performed, to understand how this biologic treatment approach compares to the traditional injective therapies available in clinical practice. Moreover, a novel coding system and 'minimum reporting requirements' are proposed to improve future research in this field and promote a better understanding of the mechanisms of action and indications. Expert opinion The main limitation in the current literature is the extreme variability of PRP products used, with often paucity or even lack of data on the biologic features of PRP, which should not be considered as a simple substance, but rather a 'procedure' requiring accurate reporting of the characteristics of the product but also all preparation and application modalities. This approach will aid in matching the optimal PRP product to specific patient factors, leading to improved outcomes and the elucidation of the cost-effectiveness of this treatment.
- Published
- 2020